To the full analysis
Buyback calculator for Shanghai Fosun Pharmaceutical (Group)
Shanghai Fosun Pharmaceutical (Group) stock: key metrics
600196.SSShanghai Fosun Pharmaceutical (Group) had an operating margin of 6.1% and a return on invested capital (ROIC) of 2.6% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 21.7% | 8.2% | no data |
| 2007 | 27.1% | 19.9% | no data |
| 2008 | 28.1% | 3.7% | no data |
| 2009 | 32.2% | 4.8% | 64.9% |
| 2010 | 34.5% | 25.0% | no data |
| 2011 | 38.5% | 24.4% | 18.0% |
| 2012 | 43.8% | 8.1% | 21.3% |
| 2013 | 44.3% | 10.8% | 15.8% |
| 2014 | 43.9% | 19.9% | no data |
| 2015 | 49.8% | 26.2% | no data |
| 2016 | 53.8% | 23.2% | 19.2% |
| 2017 | 58.8% | 22.0% | 16.9% |
| 2018 | 58.3% | 14.2% | 10.9% |
| 2019 | 59.6% | 15.7% | 11.6% |
| 2020 | 54.5% | 15.6% | no data |
| 2021 | 48.0% | 16.2% | no data |
| 2022 | 47.1% | 10.6% | no data |
| 2023 | 47.5% | 8.0% | no data |
| 2024 | 47.8% | 10.3% | 6.7% |
| 2025 | 46.1% | 6.1% | 8.1% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | no data | 6.1% | no data |
| 2007 | no data | 13.2% | no data |
| 2008 | no data | 2.4% | no data |
| 2009 | 38.6% | 2.1% | 21.7% |
| 2010 | no data | 10.0% | no data |
| 2011 | 11.9% | 10.2% | 5.2% |
| 2012 | 11.5% | 3.5% | 6.1% |
| 2013 | 10.3% | 5.1% | 5.4% |
| 2014 | no data | 9.6% | no data |
| 2015 | no data | 11.1% | no data |
| 2016 | 12.6% | 10.6% | 6.4% |
| 2017 | 12.3% | 9.9% | 5.0% |
| 2018 | 9.7% | 6.6% | 3.8% |
| 2019 | 10.4% | 7.5% | 4.4% |
| 2020 | no data | 7.3% | no data |
| 2021 | no data | 8.9% | no data |
| 2022 | no data | 6.4% | no data |
| 2023 | no data | 4.2% | no data |
| 2024 | 5.9% | 4.9% | 2.4% |
| 2025 | 6.9% | 2.6% | 2.8% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak since 13 Nov 2026, previously Neutral
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.